CAI · Caris Life Sciences, Inc. · Executive Compensation
$23.96
-0.53 (-2.16%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$6.87B
Shares
286.78M
Volume · Nov 12
3.57M
Avg daily vol (3M)
4.67M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David Dean Halbert | Chief Executive Officer | $20,350,571 |
| David Spetzler | President | $11,583,227 |
| J. Russel Denton | Senior Vice President, General Counsel and Secretary | $5,354,614 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David Dean Halbert | Chief Executive Officer | $2,250,000 |
| David Spetzler | President | $1,213,800 |
Leadership
- David Dean Halbert CEO
- Jeffrey Vacirca CEO
- Brian J. Brille Chairman
- Jon S. Halbert Chairman
- Peter M. Castleman Chairman
- Danny Phillips CFO
- Joseph E. Gilliam COO
- J. Russel Denton General Counsel
- Laura I. Johansen General Counsel
Key facts
CIK
2019410
CUSIP
142152107
13F (30d)
212 filings
200 filers
Visit website
Investor relations